Published on
Mar 5, 2021
CytoDyn to Hold Webcast on March 8 to Provide Overview of CD12 Trial Data and Regulatory Path Forward with the U.S., U.K....
VANCOUVER, Washington, March 05, 2021 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTC.QB: CYDY), (“CytoDyn” or the “Company"), a late-stage biotechnology company developing Vyrologix™ (leronlimab-PRO 140), a CCR5 antagonist with the potential for multiple …
Distribution channels:
